In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 12 selected

Guidance programme

Showing 351 to 360 of 408

TitleTypeExpected publication date
Suspected sepsis in pregnancy: recognition, diagnosis and early managementNICE guideline
Suspected sepsis in under 16s: recognition, diagnosis and early managementNICE guideline
Suspected sepsis: recognition, diagnosis and early managementNICE guidelineTBC
Suspected sepsis: recognition, diagnosis and early management - procalcitonin testingNICE guideline
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]Technology appraisal guidance
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413Technology appraisal guidance
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Tarlatamamb for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]Technology appraisal guidanceTBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Technology appraisal guidanceTBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All